BeiGene, Ltd. displays a strong series of developments in Q3/4 2024. It has made significant advancements in acquiring global licensing for its
MAT2A inhibitor and securing notable deals like a $1.5B deal with CSPC for its novel cancer drug targetting 15% cancer types. A proposal for a
name change to 'BeOne Medicines' is announced in line with its commitment to unite global community against cancer. The firm also demonstrated extensive growth in its
oncology pipeline as evident by earning Buy ratings. BeiGene's shares also showed a 32% surge within a month. Moreover, the
European Commission approved BeiGene's
TEVIMBRA for treating advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer along with it receiving
FDA approval. Despite several key advancements, BeiGene saw a 15% pullback along with a notable insider sale by CFO Julia Wang, opening it up to drastic measures by institutional owners, who hold 42% of shares. Moreover, BeiGene faced a substantial loss with the untimely demise of board member Donald Glazer.
BeiGene, Ltd. News Analytics from Mon, 26 Feb 2024 08:00:00 GMT to Wed, 18 Dec 2024 08:39:17 GMT -
Rating 1
- Innovation 9
- Information 9
- Rumor 5